Symbol="IMAB"
AssetType="Common Stock"
Name="I-Mab"
Description="I-Mab, a clinical-stage biopharmaceutical company, discovers, develops and markets biologics to treat cancer and autoimmune disorders. The company is headquartered in Shanghai, the People's Republic of China."
CIK="1778016"
Exchange="NASDAQ"
Currency="USD"
Country="China"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="SUITE 802, WEST TOWER, OMNLVISION, 88 SHANGKE ROAD, PUDONG DISTRICT, SHANGHAI, CHINA"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="237803000"
EBITDA="-1859417984"
PERatio="None"
PEGRatio="None"
BookValue="36.25"
DividendPerShare="0"
DividendYield="0"
EPS="-3.88"
RevenuePerShareTTM="-2.685"
ProfitMargin="0"
OperatingMarginTTM="8.46"
ReturnOnAssetsTTM="-0.242"
ReturnOnEquityTTM="-0.637"
RevenueTTM="-221563008"
GrossProfitTTM="41594000"
DilutedEPSTTM="-3.88"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="1.917"
AnalystTargetPrice="32.07"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="2.545"
PriceToBookRatio="0.587"
EVToRevenue="0.439"
EVToEBITDA="0.101"
Beta="0.939"
num_52WeekHigh="10.37"
num_52WeekLow="2.61"
num_50DayMovingAverage="3.029"
num_200DayMovingAverage="3.845"
SharesOutstanding="83099000"
DividendDate="None"
ExDividendDate="None"
symbol="IMAB"
open="2.86"
high="2.96"
low="2.78"
price="2.85"
volume="489288.00"
latest_trading_day="2023-07-28"
previous_close="2.79"
change="0.06"
change_percent="2.1505%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="79"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="21"
Volume_recent_avg="337806"
Change_recent_avg="-0.01"
Delta_recent_avg="0.22"
Variance_recent_avg="0.11"
Change_ratio_recent_avg="-0.27"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="21"
Aroon_momentum_negative="79"
image_negative_thumbnail_id_1="128"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0048.jpeg"
image_negative_thumbnail_id_2="105"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0071.jpeg"
image_neutral_thumbnail_id_1="568"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0031.jpeg"
image_neutral_thumbnail_id_2="574"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0025.jpeg"
image_positive_thumbnail_id_1="990"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0152.jpeg"
image_positive_thumbnail_id_2="694"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0014.jpeg"
image_professor_thumbnail_id_1="1202"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0036.jpeg"
image_professor_thumbnail_id_2="1200"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0034.jpeg"
